您的位置: 首页 > 农业专利 > 详情页

COMBINAISONS PHARMACEUTIQUES DESTINEES A L'IMMUNOTHERAPIE
专利权人:
TECHNISCHE UNIVERSITAT DRESDEN
发明人:
BRENNER, SEBASTIAN,RYSER, MARTIN,RICHTER, CORNELIA,THIEME, SEBASTIAN
申请号:
CA2949885
公开号:
CA2949885A1
申请日:
2015.05.28
申请国别(地区):
CA
年份:
2015
代理人:
摘要:
The present invention relates generally to a method for regulating immune reactions and test substances useful for same. Specifically, the method of the present invention relates to the modulation of the nerve growth factor receptor p75NTR, which is expressed by plasmacytoid dendritic cells. More specifically, the invention relates to a combination comprising at least one modulator of p75NTR signalling selected from a p75NTR antagonist or p75NTR agonist and at least one TLR receptor agonist selected from an agonist of TLR7 and/or TLR9. The invention further relates to the use of a combination of antagonists and agonists of p75NTR signalling and agonists of TLR7 and/or TLR9 as vaccine adjuvants and the invention provides vaccine compositions comprising antagonists and agonists of p75NTR signalling and agonists of TLR7 and/or TLR9. The agonists and antagonists of p75NTR signalling are useful in the manufacture of drugs for controlling cytokine function, antigen presentation, activation and proliferation of lymphocytes, which is important for the treatment of a range of conditions including cancer, inflammatory conditions, immunological disorders, growth disorders, infections and any other conditions involving p75NTR signal transduction. The invention provides assays to screen for a range of agonists and antagonists of p75NTR useful in modulating cytokine function, activation and proliferation of lymphocytes. The present invention further provides, therefore, screening assays for agonists and antagonists of p75NTR-modulated immune responses.
来源网站:
中国工程科技知识中心
来源网址:
http://www.ckcest.cn/home/
相关发明人
相关专利

意 见 箱

匿名:登录

个人用户登录

找回密码

第三方账号登录

忘记密码

个人用户注册

必须为有效邮箱
6~16位数字与字母组合
6~16位数字与字母组合
请输入正确的手机号码

信息补充